Roche’s Genentech has licensed global rights to develop and commercialise another Alzheimer’s disease antibody programme from AC Immune, this time preclinical antibodies targeting the Tau protein. The deal is potentially worth more than CHF400 M (US$421 M) to AC Immune plus royalties on net sales of products emerging from the collaboration. Genentech licensed global rights to AC Immune’s anti-Abeta antibody crenezumab in 2006 and the drug candidate is currently in several Phase II clinical trials for mild-to-moderate Alzheimer’s disease.